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ABSTRACT
Diffuse large B cell lymphoma (DLBCL) is a heterogeneous group of aggressive 
lymphomas that can be classified into three molecular subtypes by gene expression 
profiling (GEP): GCB, ABC and unclassified. Immunohistochemistry-based cell 
of origin (COO) classification, as a surrogate for GEP, using three available 
immunohistochemical algorithms was evaluated in TMA-arranged tissue samples 
from 297 patients with de novo DLBCL treated by chemoimmunotherapy (R-CHOP 
and R-CHOP-like regimens). Additionally, the prognostic impacts of MYC, BCL2, 
IRF4 and BCL6 abnormalities detected by FISH, the relationship between the 
immunohistochemical COO classification and the immunohistochemical expression 
of MYC, BCL2 and pSTAT3 proteins and clinical data were evaluated.
In our series, non-GCB DLBCL patients had significantly worse progression-free 
survival (PFS) and overall survival (OS), as calculated using the Choi, Visco-Young 
and Hans algorithms, indicating that any of these algorithms would be appropriate 
for identifying patients who require alternative therapies to R-CHOP. Whilst MYC 
abnormalities had no impact on clinical outcome in the non-GCB subtype, those 
patients with isolated MYC rearrangements and a GCB-DLBCL phenotype had worse 
PFS and therefore might benefit from novel treatment approaches.
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INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is the 
most prevalent subtype of mature B-cell neoplasms 
worldwide, accounting for approximately 30% of all non-
Hodgkin lymphomas. A combination of rituximab with 
an anthracycline-based chemotherapy regimen, such as 
R-CHOP, produces a favorable outcome for most patients. 
Nevertheless, one third of patients will still relapse, of 
whom a proportion will suffer from refractory disease [1].
Although the International Prognostic Index (IPI) 
has proved to be a very useful clinical tool, and is widely 
used to risk-stratify patients [2], it is exclusively based 
on clinical variables and therefore fails to capture the 
biological heterogeneity of DLBCL, and does not identify 
potential targeted therapies.
In recent years, biological studies have shown that 
DLBCL is not a single disease but a group of disorders 
with specific signaling programs [3], some of which have 
been shown to benefit from specific novel treatments. 
Specifically, gene expression profiling (GEP) has identified 
three DLBCL subtypes: the germinal center B-cell-like 
(GCB) and the activated B cell-like (ABC) DLBCL 
subtypes, and unclassified cases (~10%). GCB patients 
tend to have better survival than the ABC and unclassified 
DLBCL patients when treated by chemotherapy, with 
or without rituximab [4, 5]. New treatments including 
ibrutinib [6] or immunomodulators such as lenalidomide 
have shown very promising results in patients with an 
ABC or non-GCB DLBCL subtype [7], as determined 
by GEP and immunohistochemistry in separate clinical 
trials. Although preferential activity with bortezomib for 
cases with the refractory ABC/non-GCB subtype was 
suggested early on [8], recently published data concerning 
frontline VR-CAP do not indicate a significant difference 
with R-CHOP in the non-GCB type DLBCL [9], and the 
differential efficacy remains controversial.
For this reason, identification of cases that will not 
respond to conventional approaches but might benefit 
from targeted therapy has become a matter of considerable 
interest.
Several studies have demonstrated that 
immunohistochemical (IHC) algorithms can reproduce 
GEP classification and potentially be used for the 
prognostic stratification of DLBCL [10–12]. Of these, 
the Hans, Visco-Young and Choi algorithms have shown 
the highest concordance with the cell of origin (COO) 
as defined by GEP. However, several clinical studies 
investigating the ability of COO IHC algorithms to 
prognostically stratify DLBCL patients treated with 
anthracycline-based chemotherapy with or without 
rituximab have yielded conflicting results [13–18].
Recurrent non-random chromosomal rearrangements 
leading to the deregulated expression of MYC, BCL6 and 
BCL2 in DLBCLs have been reported to have mixed 
associations with prognosis [17, 19–24]. Concurrent MYC 
and BCL2 rearrangements [20, 25–27] are associated 
with poor outcome in DLBCL and are commonly found 
in GCB-type DLBCLs [28]. IRF4 rearrangements are 
associated with a GCB phenotype in grade 3FL and 
DLBCL, and with younger age and favorable outcome 
[29]. Constitutive activation of STAT3 is preferentially 
detected in the non-GCB subtype of DLBCL, and seems 
to favor proliferation and survival of lymphoma cells [30]. 
However, the prognostic impact of this molecule is yet to 
be established.
In an attempt to confirm that IHC algorithms can 
be used to prognostically stratify DLBCL patients, we 
compared the Hans, Choi and Visco-Young algorithms 
in a cohort of 297 diagnostic samples from patients with 
R-CHOP-treated DLBCL. Also, to establish whether 
deregulation of specific oncogenes may further classify 
COO-based DLBCL subtypes, adding meaningful 
prognostic information, we performed FISH of BCL6, 
BCL2, IRF4 and MYC and evaluated the expression of 
MYC, BCL2, BCL6 and pSTAT3 proteins in the same 
samples.
RESULTS
The COO of 272 (91%), 282 (95%) and 275 
(92%) of the 297 DLBCL tumor samples could be 
classified by the Hans, Visco-Young and Choi algorithms, 
respectively (Figure 1). No significant differences were 
observed between the IHC phenotypes with respect to 
age or extranodal involvement. However, the non-GCB 
group of patients had a higher IPI score (p≤0.011) and 
more frequently presented with stage III or IV disease 
(p≤0.001). Non-GCB cases had higher LDH levels and 
worse performance status than GCB cases as classified 
by the Hans and Visco-Young algorithms (Table 1 and 
Supplementary Tables 1 and 2).
Comparing GEP with the results of the Hans, Choi 
and Visco-Young algorithms, revealed discrepancies in the 
COO classification in only 14%, 13% and 8% patients, 
respectively [12].
MYC, BCL2, BCL6 and pSTAT3 protein 
expression and correlation with COO 
phenotypes
45% of the evaluable samples (62/140) showed 
MYC overexpression. 72% and 64% of patients with 
MYC protein overexpression also had high LDH levels 
(p=0.011) and high IPI scores (p=0.029), respectively 
(Supplementary Table 3). MYC overexpression was 
not associated with a particular COO phenotype 
(Supplementary Table 4). MYC and BCL2 double-
positivity was found in 34% of evaluable cases (42/123 
cases). As previously described, MYC and BCL2 double-
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Figure 1: A. Immunohistochemistry was used to identify DLBCL subtypes. A prototypical example of GCB-type DLBCL is shown, 
as classified by the three algorithms considered. The case shows positive staining for GCET1, CD10, BCL6 and negative (or below the 
threshold) staining for MUM1 and FOXP1. B. A case of non-GCB/ABC subtype, classified by the three algorithms, is shown. The case 
has immunohistochemical expression of MUM1 and FOXP1 and negative (or below the threshold) staining for Gcet1, CD10 and BCL6. 
C. FISH using the LSI MYC break-apart probe on a tissue sample of a patient with a GCB DLBCL with rearrangement of the MYC gene.
positive (DP) cases determined by IHC were commonly 
found to have a non-GCB phenotype (p=0.007, p=0.018 
and p=0.002 for the Visco-Young, Hans and Choi 
algorithms, respectively) (Supplementary Table 4). Most 
patients coexpressing the MYC and BCL2 proteins were 
aged over 60 years (74%), had stage III or IV disease 
(74%), and 36% of cases had two or more extranodal 
sites involved and were therefore associated with high-
risk IPI (p=0.003; Supplementary Table 5). 15% and 24% 
of MYC and BCL2 double-positive cases had MYC and 
BCL2 rearrangements, respectively (p=0.030 and p=0.938, 
Supplementary Table 6).
Isolated BCL2 overexpression was not associated 
with the COO classification, and there were no 
associations between BCL2 protein expression and any of 
the clinical or biological features analyzed in our series 
(data not shown).
pSTAT3 protein expression was detected in 34% 
(47/139) of evaluable cases and was associated with 
advanced-stage disease (p=0.003) and high IPI score 
(p=0.045; Supplementary Table 5). Its expression was 
more frequent in cases with elevated MYC expression 
(p=0.006) (Supplementary Table 3).
MYC, BCL6, BCL2 and IRF4 abnormalities
MYC rearrangements were observed in 7% of 
patients (15 out of 206 cases) (Table 2 and Figure 1), 30% 
of which had additional cytogenetic abnormalities, BCL2 
rearrangements and MYC gains being the most common 
added gene aberrancies (in 4 out of 13, and 2 out of 15 
evaluable cases, respectively). MYC rearrangements were 
more frequent in patients younger than 60 years of age 
(p=0.029), with more than two extranodal localizations 
(p=0.009), and in the high-risk IPI group (p=0.051). 
We found no difference in the distribution of MYC 
rearrangements with respect to the COO phenotype. No 
significant correlation was observed between the presence 
of MYC rearrangements and MYC protein expression (5 
out of 63 cases with MYC protein overexpression had 
MYC rearrangements).
MYC gains (Supplementary Table 7) were observed 
in 19% of patients and were more frequently observed in 
the group of patients with normal LDH values (p=0.032). 
Cases with MYC gains expressed MYC, BCL2 and BCL6 
protein in 31%, 56% and 84% of cases, respectively. MYC 
gains were associated with gains in BCL2 (p=0.002) and 
BCL6 (p=0.002), but there was no association with other 
cytogenetic, biological or clinical features.
BCL2 rearrangements were detected in 19% of 
patients (Table 2). There was no association between the 
presence of any type of BCL2 gene abnormality and the 
main clinical features studied. BCL2 rearrangements were 
almost entirely restricted to the GCB phenotype (Table 
1, p<0.001). There was a close correlation between the 
presence of a BCL2 rearrangement and BCL2 protein 
overexpression (p=0.003; 95% of cases with the BCL2 
rearrangement expressed the BCL2 protein; data not 
shown). BCL2 gains were observed in 14% of patients and 
were more frequently detected in the non-GCB phenotype 
group (p=0.013; 80% of cases with BCL2 amplification 
had a non-GCB phenotype; Table 1).
BCL6 rearrangements were observed in 30% (51 
out of 171) of DLBCL patients, were associated with a 
non-GCB phenotype (Table 1, p<0.001; 70% of cases)
[38] and were more frequent in the group of patients 
with elevated LDH (p=0.021) (Table 2). However, 
there was no association with other clinical features. 
BCL6 gains, observed in 17% of patients, showed 
no significant association with any of the clinical or 
phenotypic features analyzed. In contrast to the BCL6 
rearrangements, there was a direct relation between the 
presence of BCL6 gains and BCL6 protein expression 
(Table 2; p=0.02).
Double rearrangements were detected in 10 of 178 
cases: there were concurrent BCL2/MYC rearrangements 
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in 4 cases, BCL2/BCL6 rearrangements in 5 cases and 
MYC/BCL6 in 1 case. Taken together, 80% of double-
rearrangement DLBCL cases had a GCB phenotype 
(p=0.029), and there was a higher absolute proportion of 
them in patients aged over 60 years (p=0.073) and with 
elevated LDH values (p=0.053), although these trends 
were not statistically significant (Supplementary Table 
8). 37% of patients presented involvement of two or more 
extranodal sites, and 60% had stage III or IV disease. 
Considering only double-hit cases (BCL2/MYC and BCL6/
MYC patients), no significant association with any specific 
clinical or biological feature was detected, probably due to 
the small number of cases available.
IRF4 rearrangements and gains were observed in 3 
out of 76, and 4 out 41 assessable patients, respectively. 
67% and 100% of IRF4 rearrangement and gain cases, 
respectively, had a non-GCB phenotype (Table 1). There 
was no association between the IRF4 rearrangement 
and the clinical variables. An association between IRF4 
and BCL2 gains was observed (p=0.035). In contrast 
to previously published data [29], in our series, 60% of 
patients with IRF4 rearrangements were over 60 years old. 
It should be noted, however, that 60% of the patients in 
this study were older than 60 years of age.
Survival analysis
All clinical and biological variables were evaluated 
for their ability to predict response and outcome. In the 
univariate analysis, stage III-IV disease was associated 
with worse OS (p=0.016) and PFS (p<0.001), as were 
elevated LDH levels, age ≥60 years, poorer performance 
status, extranodal involvement and high IPI score. As in 
previous studies, the independent prognostic impact of all 
IPI variables was maintained in the multivariate analysis.
Considering the Visco-Young, Choi and Hans 
algorithms, the non-GCB subgroup was associated 
with significantly worse PFS (p=0.001, p=0.005 and 
p=0.003, respectively) and OS (p=0.002, p=0.001 and 
p=0.001, respectively) (Table 3 and Figure 2A and 2B). 
In the multivariate analysis (Table 4), COO classification 
remained an independent prognostic factor of PFS and OS 
for all the algorithms (Table 4, hazard ratio [HR] 1.7-2.1; 
p<0.03). The algorithms showed close agreement with 
each other, with a level of concordance of 88.6-90.3 % 
(multi-rater kappa, ḵ=0.8).
As seen in a previous study [39], patients with MYC 
rearrangements and GCB phenotype had a significantly 
shorter PFS (p=0.035, p=0.004 and p=0.021, for the 
Table 1: Clinical characteristics and differences in MYC, BCL2, BCL6, pSTAT3 and IRF4 changes according to cell 
of origin type
 Choi classification (n=275) Visco-Young classification (n=282) Hans classification (n=272)
 GCB (n=120) Non-GCB 
(n=155)
 GCB (n=112) Non-GCB 
(n=170)
 GCB (n=115) Non-GCB 
(n=157)
 
Cohort No % No % p No % No % p No % No % p
IPI score
High (3-5) 43 of 116 37 77 of 146 53 0.011 39 of 107 36 83 of 159 52 0.011 38 of 112 34 84 of 151 56 <0.001
MYC
 rMYC
 gMYC
 
9 of 85
20 of 81
 
11
25
6 of 111
17 of 102
 
6
17
 
0.176
0.179
 
9 of 79
21 of 70
 
11.5
28
6 of 120
16 of 109
 
5
15
 
0.095
0.03
 
9 of 85
21 of 80
 
11
26
6 of 116
16 of 108
 
5
15
 
0.149
0.051
BCL2
 rBCL2
 gBCL2
 
30 of 79
5 of 77
 
38
7
 
5 of 104
20 of 101
 
5
20
 
<0.001
0.011
 
30 of 78
5 of 76
 
38
7
 
6 of 107
20 of 104
 
6
19
 
0.000
0.015
 
31 of 80
5 of 77
 
39
7
 
4 of 105
20 of 103
 
4
19
 
<0.001
0.013
BCL6
 rBCL6
 gBCL6
 
11 of 72
15 of 81
 
15
19
 
38 of 92
15 of 92
 
41
16
 
<0.001
0.701
 
11 of 68
13 of 77
 
16
17
 
39 of 98
17 of 98
 
40
17
 
0.001
0.936
 
12 of 71
15 of 79
 
17
19
 
38 of 96
15 of 97
 
40
16
 
0.002
0.536
IRF4
 rIRF4
 gIRF4
 
1 of 20
0 of 9
 
5
0
 
2 of 53
4 of 30
 
4
13
 
0.623
0.333
 
1 of 16
0 of 8
 
6
0
 
2 of 58
4 of 32
 
3
12.5
 
0.524
0.393
 
1 of 22
0 of 10
 
4.5
0
 
2 of 52
4 of 30
 
4
13
 
0.659
0.3
DHL  
MYC/BCL 
2+ (n=4)
4 of 55 7 1 of 68 1.5 0.123 4 of 55 7 1 of 70 1 0.117 4 of 55 7 1 of 70 1 0.117
Abbreviations: GCB: germinal center B-cell-like; DLBCL, diffuse large B-cell lymphoma; rMYC: rearrangement of 
MYC; gMYC: gain of the MYC locus; rBCL2: rearrangement of BCL2; gBCL2: gain of BCL2 locus; rBCL6 rearrangement 
of BCL6; gBCL6: gain of BCL6 locus. IPI score ranges from 0 to 5, with 0 indicating the absence of prognostic factors 
and 5 indicating the presence of all prognostic factors. The IPI score was stratified by the proposed RIPI score. pSTAT3, 
phosphorylated STAT3 protein expression.
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Hans, Choi and Visco-Young algorithms, respectively) 
(Figure 2G, Supplementary Table 9). None of the 
algorithms was of prognostic value with respect to OS, 
although with the Visco-Young algorithm, patients with 
a GCB phenotype and MYC rearrangements showed a 
non-significant tendency towards a lower OS (p=0.098), 
(Supplementary Table 10). Neither BCL2 nor BCL6 
abnormalities had a clear impact on outcome, either in 
the series as a whole or in the specific COO subtypes. In 
contrast, in the entire series, BCL6 expression tended to be 
associated with better PFS (p=0.077) and OS (p=0.048).
In our series, patients coexpressing MYC and BCL2 
did not show worse PFS or OS. The presence of MYC, 
BCL2 and/or pSTAT3-positive protein expression was not 
associated with poorer PFS or OS. This might be due to 
the limited number of cases with available IHC data for 
these markers. Unavailability was most commonly due to 
tissue exhaustion.
DISCUSSION
Prognostic stratification of DLBCL patients has 
customarily been based on the clinical parameters 
comprising the International Prognostic Index (IPI). This 
classification continues to be the standard clinical tool for 
predicting the outcome of DLBCL patients in the rituximab 
era [40]. However, it does not capture the biological 
heterogeneity of the disease and does not identify potential 
targets for therapy. GEP studies have identified three 
subtypes of DLBCL with distinct biological signatures: the 
GCB, the ABC and the unclassified groups. Although gene 
expression in formalin-fixed paraffin-embedded tissue 
[41] is probably the preferred method for differentiating 
these two DLBCL subtypes, it is not yet available in most 
centers. Classification using digital PCR assay has shown 
promising results [41, 42]. Nevertheless, a subgroup of 
~10% of cases would remain unclassified even after using 
these methods.
Several studies have shown that IHC algorithms can 
discriminate GCB and non-GCB DLBCL subtypes with a 
high concordance with GEP, but there is still a reluctance 
to using them in the clinical setting. In this study, the 
Hans, Visco-Young and Choi algorithms were used as 
surrogates for GEP-based COO molecular classification. 
Variation due to the technique was reduced by centralized 
staining and scoring. All the IHC approaches used 
were able to distinguish the two prognostic subgroups, 
and showed substantial agreement among themselves, 
Table 2: Clinical features with respect to the presence of MYC, BCL2 and BCL6 rearrangements
 MYC
(n=15/206)
Rearranged
BCL2
(n=36/187)
Rearranged
BCL6
(n=51/171)
Rearranged
Patients, No. (%)  P  P  P
Age, years
 > 60
 ≤ 60
 
5 (36)
9 (64)
 
0.029
 
20 (62)
12 (38)
 
0.920
 
32 (65)
17 (35)
 
0.581
Ann Arbor stage
 I-II
 III-IV
 
3 (21)
11 (78)
 
0.153
 
14 (44)
18 (56)
 
0.381
 
18 (37)
30 (62)
 
0.735
LDH
 Low
 > upper limit of normal
 
3 (23)
10 (77)
 
0.097
 
10 (38)
16 (62)
 
0.835
 
12 (30)
28 (70)
 
0.021
Extranodal sites
 ≤ 1
 ≥ 2
 
5(35)
9(64)
 
0.009
 
20 (74)
7 (26)
 
0.656
 
28 (72)
11 (28)
 
0.695
ECOG †
 PS ≤ 1
 PS > 1
 
11(79)
3 (21)
 
0.473
 
18 (69)
8 (31)
 
0.780
 
25 (64)
14 (36)
 
0.659
IPI score ‡
 Low (0-2)
 High (3-5)
 
4 (29)
10 (71)
 
0.051
 
19 (58)
14 (42)
 
0.268
 
24 (50)
24 (50)
 
0.533
Abbreviations: IPI, International Prognostic Index; LDH, lactate dehydrogenase; †ECOG PS, ranging from 0 to 4, where 
a higher score indicates greater impairment. ‡ IPI score, ranging from 0 to 5, where 0 indicates the absence of prognostic 
factors, and 5 indicates the presence of all prognostic factors. The IPI score was stratified by the proposed RIPI score.
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Table 3: Progression-free survival (PFS) and overall survival (OS) with respect to the IPI, cell of origin, 
immunohistochemical double-positive cases and gene abnormalities of the MYC, BCL2 and BCL6 loci
 PFS OS
 RR (95% CI) p RR (95% CI) p
Age, years
 > 60
 ≤ 60
 
13 (0.8-2.1)
 
0.198
 
2.2 (1.3-3.7)
 
0.003
Ann Arbor stage
 I-II
 III-IV
 
2.4 (1.5-3.9)
 
<0.001
 
1.8 (1.1-2.9)
 
0.019
LDH
 Low
 > upper limit of normal
 
2.5 (1.5-4.1)
 
<0.001
 
2.4 (1.4-4.2)
 
0.002
Extranodal sites
 ≤ 1
 ≥ 2
 
2.1 (1.3-3.2)
 
0.001
 
2.0 (1.3-3.3)
 
0.003
ECOG †
 PS ≤ 1
 PS > 1
 
2.3 (1.5-3.6)
 
<0.001
 
2.6 (1.6-4.2)
 
<0.001
IPI score ‡
 Low (0-2)
 High (3-5)
 
2.5 (1.6-3.9)
 
<0.001
 
2.7 (1.7-4.4)
 
<0.001
Cell of origin subtype
Hans Classification
 Non-GCB
 GCB
Choi Classification
 Non-GCB
 GBC
Visco-Young Classification
 Non-GCB
 GCB
 
 
1.9 (1.2-3.0)
 
 
1.8 (1.2-2.9)
 
 
2.3 (1.4-3.7)
 
 
0.003
 
 
0.005
 
 
0.001
 
 
2.3 (1.3-3.8)
 
 
 
1.9 (1.1-3.1)
 
 
2.3 (1.3-4.0)
 
 
0.001
 
 
 
0.010
 
 
0.002
MYC
 rMYC
 gMYC
MYC protein expression
 
1.5 (0.6-3.7)
0.5 (0.2-1.2)
0.9 (0.5-1.6)
 
0.279
0.173
0.803
 
1.1 (0.4-3.2)
0.6 (0.3-1.4)
0.9 (0.5-1.8)
 
0.738
0.273
0.979
BCL2
 rBCL2
 gBCL2
 BCL2 protein expression
 
0.7 (0.4-1.6)
0.8 (0.3-1.8)
1.2 (0.7-2.2)
 
0.477
0.648
0.410
 
0.3 (0.1-1.0)
1.1 (0.5-2.5)
1.0 (0.5-2.0)
 
0.067
0.687
0.918
BCL6
 rBCL6
 gBCL6
 BCL6 protein expression
 
1.0 (0.6-1.9)
0.7 (0.3-1.5)
0.6 (0.4-1.0)
 
0.784
0.384
0.077
 
1.2 (0.6-2.1)
0.8 (0.4-1.6)
0.6 (0.4-1.0)
 
0.514
0.565
0.048
pSTAT3 protein expression 0.9 (0.5-1.5) 0.739 0.8 (0.4-1.5) 0.484
IRF4
 r IRF4
 g IRF4
 
-
0.9 (0.1-7.4)
 
0.450
0.981
 
-
0.4 (0.1-3.4)
 
0.500
0.440
Double-HIT (FISH)
c-MYC+/BCL2+(IHC)
0.8 (0.2-4.6)
1.1 (0.6-2.0)
0.874
0.625
0.6 (0.1-4.7)
0.9 (0.4-1.8)
0.646
0.813
Abbreviations: rMYC: rearrangement of MYC; gMYC: gain of MYC locus; rBCL2: rearrangement of BCL2; gBCL2: gain of 
BCL2 locus; rBCL6 rearrangement of BCL6; gBCL6: gain of BCL6 locus; DLBCL, diffuse large B-cell lymphoma; ECOG 
PS, Eastern Cooperative Oncology Group performance status; GCB, germinal center B-cell-like; GEP, gene expression 
profiling; IPI, International Prognostic Index; DHL, double-hit lymphoma; IHC, immunohistochemistry. ‡ The IPI score 
ranges from 0 to 5, with 0 indicating the absence of prognostic factors, and 5 indicating the presence of all prognostic 
factors. The IPI score was stratified by the proposed RIPI score.
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Figure 2: Univariate prognostic analysis of progression-free survival (PFS) and overall survival (OS). PFS and OS 
of GCB and non-GCB DLBCL using the Hans (A and B), Visco-Young (C and D), and Choi (E and F) algorithms. (G-I) PFS of MYC 
rearrangements in GCB-DLBCL patients using the Visco-Young, Han and Choi algorithms, respectively.
Abbreviations: IPI, International Prognostic Index; ‡ The IPI score ranges from 0 to 5, with 0 indicating the absence of prognostic factors and 5 indicating 
the presence of all prognostic factors. The IPI score was stratified by the proposed RIPI score. IHC DP: Immunohistochemical double-positive.
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and a similar correlation with GEP [12]. The results 
were comparable to those we and other researchers had 
obtained in previous studies [12, 43]. In agreement with 
previous reports [10, 44, 45], the non-GCB subgroup had 
a worse outcome, with a shorter PFS and OS, and this 
prognostic impact was maintained in the multivariate 
analysis. These results indicate that non-GCB patients 
require novel treatment approaches, including the 
addition of novel compounds, in order for the responses 
to be sustained. Indeed, a number of different new drugs 
including lenalidomide, some proteasome inhibitors, and 
the BTK inhibitor ibrutinib (PCI-32765) have recently 
shown promising results, especially in non-GCB/ABC 
DLBCL patients [7, 46–49]. Whether IHC and GEP are 
equally capable of distinguishing patients who could 
benefit from these novel compounds requires further 
investigation since the results published so far emerged 
from different methods of determination.
To refine the prognostic stratification of patients 
after GCB/non-GCB IHC classification, we analyzed the 
effect of MYC, BCL2, BCL6 and IRF4 abnormalities as 
detected by FISH. We detected MYC rearrangements in 7% 
of the cases, only 30% of which had additional cytogenetic 
abnormalities. The negative impact on prognosis for the 
isolated MYC rearrangement, as a single cytogenetic 
abnormality, was restricted to patients with a GCB 
phenotype and was associated with a shorter PFS. Thus, 
although the prognostic implication of the finding was not 
confirmed in the multivariate analysis, probably because 
of the small number of patients with this abnormality, 
our results [39] confirm that the favorable prognosis of 
GCB-type DLBCL is overcome by the negative effect 
of MYC rearrangements. For this reason, a systematic 
investigation of MYC rearrangements, at least within the 
GCB subgroup of patients, would be worthwhile. Despite 
their lower PFS, these patients did not have a significantly 
worse OS, indicating that these particular cases may be 
more aggressive but can be rescued with savage therapies. 
Together, these findings suggest that GCB-type DLBCL 
patients carrying a MYC rearrangement would probably 
benefit from treatment strategies other than R-CHOP, for 
example, more aggressive chemotherapy schemes such 
as R-DAEPOCH, or the addition of MYC inhibitors. 
Indeed, several small molecules have been identified as 
MYC inhibitors, although none is currently in clinical use 
[50]. In a recently employed approach, MYC expression 
is blocked by impairing a BET bromodomain protein, 
a strategy that has proved effective both in vitro and in 
xenograft models in a range of hematological neoplasms, 
including Burkitt lymphoma [51–53]. It should be noted 
that MYC rearrangements and MYC expression were not 
correlated in this study, indicating that MYC expression 
might not be the best screening method for detecting MYC 
rearrangements in cases of DLBCL NOS. Almost half 
of the patients expressing MYC protein also had a high 
level of pSTAT3 expression. pSTAT3 was preferentially, 
but not exclusively, overexpressed in the non-GCB type 
DLBCL cases [30, 34], but, in contrast to other groups 
[54, 55], was not associated with an unfavorable outcome. 
Thus, our findings are consistent with those of previous 
studies demonstrating that pSTAT3 signaling is involved 
in regulating MYC expression [56], so pSTAT3 inhibitors 
could also be used in those cases [57, 58].
As in previous studies, double-hit DLBCLs seem to 
be restricted to GCB-type DLBCLs. However, the small 
number (5/100) and the short follow-up of these cases 
prevented us from determining the prognostic impact in 
terms of OS and PFS. Most patients with concurrent MYC 
and BCL2 overexpression had high-risk IPI features and, 
consistent with previous findings, this phenotype was 
found more frequently than the double-hit with FISH and, 
unlike with true double-hits, was associated with a non-
Table 4: Multivariate prognostic analysis of progression-free survival (PFS) and overall survival (OS) according to 
COO classification algorithms
 PFS OS
 RR (95% CI) p RR (95% CI) p
IPI score ‡ 2.3 (1.5-3.6) <0.001 2.49 (1.5-4.0) <0.001
Choi classification 1.7 (1.1-2.7) 0.016 1.7 (1.1-2.8) 0.027
IPI score ‡ 2.2 (1.4-3.4) <0.001 2.3 (1.4-3.7) 0.001
Hans classification 1.7 (1.1-2.8) 0.015 2.0 (1.2-3.4) 0.007
IPI score ‡ 2.2 (1.4-3.4) <0.001 2.4 (1.5-4.0) <0.0001
Visco-Young 
classification
2.1 (1.3-3.5) 0.003 2.1(1.2-3.6) 0.006
Abbreviations: IPI, International Prognostic Index; ‡ The IPI score ranges from 0 to 5, with 0 indicating the absence of 
prognostic factors, and 5 indicating the presence of all prognostic factors. The IPI score was stratified by the proposed RIPI 
score.
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GCB phenotype [33, 59, 60]. Notably, only 15% and 24% 
of double-IHC cases had MYC and BCL2 rearrangements, 
respectively, suggesting that there must be other 
mechanisms that induce MYC and BCL2 overexpression.
In our cohort, BCL2 rearrangements, which were 
observed in 19% of the patients, were also mainly 
restricted to the GCB phenotype [22]. However, in contrast 
to the results from previously published series [22, 61], we 
found no clear negative effect on those patients’ outcome, 
possibly due to the small number of cases featuring the 
abnormality. Also, the adverse prognostic implication 
of BCL2 rearrangements might apply only to younger 
patients, so the different selection criteria used in the 
studies might explain the observed differences [62]. 
Nevertheless, BCL2 inhibition is an attractive target for 
therapy, as illustrated by the fact that at least three BCL2 
antagonists are currently undergoing clinical trials for 
cancer treatment [63].
In accordance with previous findings, BCL6 
rearrangements that were usually detected in the non-
GCB patient group [38] were not clearly associated with 
BCL6 protein overexpression, and their detection was 
of no independent prognostic consequence with respect 
to OS or PFS. The prognostic contribution of BCL6 
protein expression remains controversial [64–66] and, as 
with some previous studies, we have shown that BCL6 
expression is associated with a better OS in the rituximab 
era. Since BCL6 expression is almost completely restricted 
to germinal center cells and some lymphomas, BCL6 is an 
attractive target for therapy with several specific BCL6 
inhibitors currently being investigated [67].
In summary, our results confirm that COO 
classification based on IHC is a reproducible and practical 
approach to stratifying DLBCL patients into GCB and 
non-GCB phenotypes, the latter being associated with 
a higher risk of progression and reduced survival when 
conventional R-CHOP regimens are used. These patients 
might benefit from treatment with novel compounds that 
target signaling pathways known to be constitutively 
activated in this particular lymphoma subtype.
Identification of MYC rearrangements enables 
GCB-DLBCLs to be stratified into prognostic groups. 
GCB patients with isolated MYC rearrangements have a 
higher risk of progression and might benefit from adding 
new therapeutic approaches, including drugs that inhibit 
MYC function. Despite the lack of prognostic information, 
identification of certain proteins, such as BCL6 or 
pSTAT3, might be of interest as potential druggable target 
molecules.
PATIENTS AND METHODS
Patient selection
The study population consisted of a retrospective 
series of 297 unselected de novo cases of DLBCL 
obtained from various centers in Spain (153 cases), and 
other institutions involved in the International DLBCL 
Rituximab-CHOP Consortium Program Study in the 
USA (144 cases). Some of these cases have already 
been published [31, 32]. The study was reviewed and 
approved by each of the participating Institutional 
Review Boards. The overall collaborative study and the 
study protocol and sampling methods were approved 
by the Institutional Review Board of the Hospital 
Universitario Marqués de Valdecilla/IDIVAL, Spain. 
Histopathological criteria used for their diagnosis and 
classification were those of the WHO Classification 
[3]. Cases associated with HIV or HCV infections or 
previous immunosuppressive treatments were excluded, 
as were cases diagnosed as T-cell histiocyte-rich B-cell 
lymphoma, primary mediastinal B-cell lymphoma cases, 
cutaneous LBCL, intravascular LBCL, EBV+DLBCL 
and those histologically associated with a follicular 
lymphoma component. All patients were treated as part 
of their routine care with standard treatment protocols 
using a combination of anthracycline-based regimens (6-8 
cycles in most cases) and rituximab. Follow-up data on 
progression-free survival (PFS) and overall survival (OS) 
were available for 279 (94%) and 283 (95%) patients, 
respectively.
Immunohistochemistry, TMA construction and 
FISH analysis
Histopathological evaluation, 
immunohistochemistry and FISH analysis were performed 
in a central laboratory by experienced hematopathologists 
and cytogeneticists. All DLBCL cases were histologically 
confirmed and representative areas were selected. 
Detailed IHC staining procedures are described in the 
Supplementary Data. The cut-offs for the IHC markers 
were BCL2 >70%, MYC >40% and pSTAT3 >10%, based 
on published data [33, 34]. Scoring of GCET1, MUM1, 
CD10, BCL6, and FOXP1 was based on the cut-offs 
used by Choi et al [11], Hans et al [10] and Visco Young 
[35]. Immunoreactivity was scored by two independent 
pathologists (SMM and SMU) and the percentage of 
tumor-cell staining was estimated by visual inspection 
and categorized into the appropriate decile. Disagreements 
were resolved by joint review using a multiheaded 
microscope. For each case the most representative core, 
with the highest percentage of neoplastic cells, was 
selected.
FISH analyses were performed on 3-μm TMA tissue 
sections following standard procedures [36, 37] (see 
Supplementary Data for details). At least 100 intact, non-
overlapping nuclei were analyzed from each TMA core. 
Discordant duplicates were reevaluated by two observers 
(AB, SG). Nuclei were scored as rearranged if at least 
one split orange-green signal was observed. Gains were 
reported when three or more fusion signals were observed. 
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Control values were previously established on the basis of 
samples of 10 controls (mean plus or minus three standard 
deviations). The cut-off values for chromosome gain or 
rearrangement were 15% in each case.
Statistical analysis
Patient characteristics and response rates were 
compared using the X2 or Fisher’s exact test, depending on 
the number of observations. PFS was defined as the time 
from initial diagnosis to progressive disease under therapy, 
failure to achieve complete remission, additional therapy, 
relapse, or death from any cause. OS was defined as the 
time from initial diagnosis to death. PFS and OS were 
analyzed using the log-rank test and illustrated as Kaplan-
Meier plots. A Cox proportional hazards multivariate 
regression model was derived. Differences between the 
results of comparative tests were considered significant 
for two-sided values of p<0.05. The multi-rater kappa was 
used to assess the concordance between the algorithms.
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